The announcement comes as Sanofi seeks to defend its No.2 spot in a global diabetes market worth over $40 billion, at a time when top-selling drug Lantus, the world's most prescribed insulin, is set to lose patent protection early next year.
Sanofi and Medtronic will initially cooperate on developing drug-device combinations and offering care management services for diabetes patients.
Depending on the results, they will consider other areas for collaboration, the companies said in a statement.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity